Literature DB >> 33057964

GNG13 Is a Potential Marker of the State of Health of Alzheimer's Disease Patients' Cerebellum.

Cristina Sanfilippo1, Giuseppe Musumeci2, Maria Kazakova3, Venera Mazzone4, Paola Castrogiovanni2, Rosa Imbesi2, Michelino Di Rosa5.   

Abstract

Brain regions such as the cerebellum (CB) have been neglected for a long time in the study of Alzheimer's disease (AD) pathogenesis. In reference to a new emerging hypothesis according to which there is an altered cerebellar synaptic processing in AD, we verified the possible role played by new biomarkers in the CB of AD patients compared with not-demented healthy control subjects (NDHS). Using a bioinformatics approach, we have collected several microarray datasets and obtained 626 cerebella sample biopsies belonging to subjects who did not die from causes related to neurological diseases and 199 cerebella belonging to AD. The analysis of logical relations between the transcriptome dataset highlighted guanine nucleotide-binding protein (G protein) gamma 13 (GNG13) as a potential new biomarker for Purkinje cells (PCs). We have correlated GNG13 expression levels with already widely existing bibliography of PC marker genes, such as Purkinje cell protein 2 (PCP2), Purkinje cell protein 4 (PCP4), and cerebellin 3 (CBLN3). We showed that expression levels of GNG13 and PCP2, PCP4, and CBLN3 were significantly correlated with each other in NDHS and in AD and significantly reduced in AD patients compared with NDHS subjects. In addition, we highlighted a negative correlation between the expression levels of PC biomarkers and age. From the outcome of our investigation, it is possible to conclude that the identification of GNG13 as a potentially biomarker in PCs represents also a state of health of CB, in association with the expression of PCP2, PCP4, and CBLN3.

Entities:  

Keywords:  Alzheimer’s disease; Bioinformatics; Cerebellum; GNG13; Purkinje cells

Year:  2020        PMID: 33057964     DOI: 10.1007/s12031-020-01726-1

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  91 in total

1.  The cerebellum contributes to somatosensory cortical activity during self-produced tactile stimulation.

Authors:  S J Blakemore; D M Wolpert; C D Frith
Journal:  Neuroimage       Date:  1999-10       Impact factor: 6.556

2.  Alzheimer's disease: amyloid plaques in the cerebellum.

Authors:  H Braak; E Braak; J Bohl; W Lang
Journal:  J Neurol Sci       Date:  1989-11       Impact factor: 3.181

3.  Emotion processing in Alzheimer's disease.

Authors:  R S Bucks; S A Radford
Journal:  Aging Ment Health       Date:  2004-05       Impact factor: 3.658

Review 4.  Anatomical and physiological foundations of cerebellar information processing.

Authors:  Richard Apps; Martin Garwicz
Journal:  Nat Rev Neurosci       Date:  2005-04       Impact factor: 34.870

Review 5.  Alzheimer's disease.

Authors:  Kaj Blennow; Mony J de Leon; Henrik Zetterberg
Journal:  Lancet       Date:  2006-07-29       Impact factor: 79.321

6.  Cbln1 is essential for interaction-dependent secretion of Cbln3.

Authors:  Dashi Bao; Zhen Pang; Marc A Morgan; Jennifer Parris; Yongqi Rong; Leyi Li; James I Morgan
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

Review 7.  Autism spectrum disorder and the cerebellum.

Authors:  Esther B E Becker; Catherine J Stoodley
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

8.  Cerebellar Purkinje cell markers are expressed in retinal bipolar neurons.

Authors:  A S Berrebi; J Oberdick; L Sangameswaran; S Christakos; J I Morgan; E Mugnaini
Journal:  J Comp Neurol       Date:  1991-06-22       Impact factor: 3.215

Review 9.  Consensus paper: the role of the cerebellum in perceptual processes.

Authors:  Oliver Baumann; Ronald J Borra; James M Bower; Kathleen E Cullen; Christophe Habas; Richard B Ivry; Maria Leggio; Jason B Mattingley; Marco Molinari; Eric A Moulton; Michael G Paulin; Marina A Pavlova; Jeremy D Schmahmann; Arseny A Sokolov
Journal:  Cerebellum       Date:  2015-04       Impact factor: 3.847

10.  Next-generation transgenic mice for optogenetic analysis of neural circuits.

Authors:  Brent Asrican; George J Augustine; Ken Berglund; Susu Chen; Nick Chow; Karl Deisseroth; Guoping Feng; Bernd Gloss; Riichiro Hira; Carolin Hoffmann; Haruo Kasai; Malvika Katarya; Jinsook Kim; John Kudolo; Li Ming Lee; Shun Qiang Lo; James Mancuso; Masanori Matsuzaki; Ryuichi Nakajima; Li Qiu; Gregory Tan; Yanxia Tang; Jonathan T Ting; Sachiko Tsuda; Lei Wen; Xuying Zhang; Shengli Zhao
Journal:  Front Neural Circuits       Date:  2013-11-26       Impact factor: 3.492

View more
  4 in total

1.  Discovery of Molecular Networks of Neuroprotection Conferred by Brahmi Extract in Aβ42-Induced Toxicity Model of Drosophila melanogaster Using a Quantitative Proteomic Approach.

Authors:  Sayali Chandrashekhar Deolankar; Mohd Altaf Najar; Poornima Ramesh; Anagha Kanichery; Avinash K Kudva; Shamprasad Varija Raghu; T S Keshava Prasad
Journal:  Mol Neurobiol       Date:  2022-10-20       Impact factor: 5.682

Review 2.  Subtype-dependent regulation of Gβγ signalling.

Authors:  Mithila Tennakoon; Kanishka Senarath; Dinesh Kankanamge; Kasun Ratnayake; Dhanushan Wijayaratna; Koshala Olupothage; Sithurandi Ubeysinghe; Kimberly Martins-Cannavino; Terence E Hébert; Ajith Karunarathne
Journal:  Cell Signal       Date:  2021-02-11       Impact factor: 4.850

3.  Identification of Molecular Signatures and Candidate Drugs in Vascular Dementia by Bioinformatics Analyses.

Authors:  Jun Shu; Wenshi Wei; Li Zhang
Journal:  Front Mol Neurosci       Date:  2022-02-11       Impact factor: 5.639

4.  Experimental Evidence of Buyang Huanwu Decoction and Related Modern Preparations (Naoxintong Capsule and Yangyin Tongnao Granule) in Treating Cerebral Ischemia: Intestinal Microorganisms and Transcriptomics in Rats.

Authors:  Junjun Yin; Jiehong Yang; Buchang Zhao; Chao Zhao; Wei Fu; Yu He; Miaolin Zeng; Yuting Yang; Xiaoyu Wei; Zhishan Ding; Jingxian Bai; Haitong Wan; Huifen Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2022-09-21       Impact factor: 2.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.